Navigation Links
Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Date:6/3/2008

ng additional studies with tanespimycin with the goal of further characterizing the drug candidate's safety and efficacy profile and potentially paving the way to a registration program. Patients currently enrolled in the ongoing Phase 2 trial of tanespimycin plus trastuzumab will continue on study per protocol. Kosan does not plan to enroll additional patients in this trial.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). KOS-1584 epothilone product candidate is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's epothilone program is licensed to Bristol-Myers Squibb. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. Kosan recently agreed to be acquired by Bristol-Meyers Squibb. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding the further development and potential safety, efficacy, regulatory status, commercial potential and other characteristics of Kosan's product candidates; the continuation of current clinical trials; the initia
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
2. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
3. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
4. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
7. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
8. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
9. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
10. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
11. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting ... China,s orthopedic instrument industry has ... size rising from 3.28 billion yuan in 2006 to ...
(Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... III Study Results Presented At ASCO -- , ... with,pegylated interferon alfa-2b in stage III melanoma had ... to the results of the largest adjuvant trial ... of the Phase,III study, led by the European ...
... - MGI Pharma, Inc.,(Nasdaq:MOGN), a biopharmaceutical company ... highlights of data presentations made,during the 2007 ... Dacogen (decitabine) for Injection was the subject ... data in older,patients with acute myelogenous leukemia ...
Cached Medicine Technology:Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10
(Date:7/9/2014)... -- Vasectomy was associated with a small increased risk ... or lethal prostate cancer according to a new study ... found that the association remained even among men who ... lethal cancer cannot be explained by diagnostic bias. It ... to look at the link between vasectomy and prostate ...
(Date:7/9/2014)... heretofore hidden ways that cells are regulated, scientists at ... cancer cells more likely to metastasize. , What,s more, ... by blocking two other proteins that are normally linked ... processes could have unexpected ties. , The study, ... Nature , points to the possibility of new cancer ...
(Date:7/9/2014)... have found that fecal transplantation is effective and safe ... This is the result of a study led by ... Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. The ... advance of print in the American Journal of ... C. diff , has increased to epidemic proportions over ...
(Date:7/9/2014)... in French . ... old teens, including brain structure and function, personality, life experiences ... go on to develop binge drinking within the next two ... variables such as life events and a family history of ... Whether or not the child had had a single drink ...
(Date:7/9/2014)... World Cup highlights, Brian Williams refreshing old school rap ... on railings. A University of Colorado Cancer Center study ... that YouTube also allows researchers, journals, and health advocates ... skin cancer and prevention. , "No matter what field ... we communicate around the world," says Chante Karimkhani, MD ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:What drives a child to abuse alcohol? 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... Feb. 19 Given the growing strain placed ... demand for data processing and storage, corporations have ... energy efficiencies immediately. However, according to a Siemens ... to best accomplish new efficiency expectations. The new ...
... of HIEs through American Recovery and Reinvestment Act ... for the integration of health care and technology ... of 2009, Shared Health, one of the largest ... the U.S., has already shown success in implementing ...
... in Washington , D.C. ... 19 At the 6th Annual World Health Care ... driving the $2.4 trillion health care industry. From corporate ... who are responsible for purchasing health care to the ...
... A pair of blood pressure medicines helps maintain proper ... News) -- A combination of two blood pressure-lowering drugs ... percent in people with type 2 diabetes, according to ... more than 11,000 patients. , The patients were randomly ...
... 19 Healthcare has always been a vital issue for ... new industry -- financial wellness. The two are far more ... Press and AOL Health found that debt stress is a ... more likely to have health problems, 20% more likely to ...
... BOSTON, Feb. 19 Solos Endoscopy, Inc. (Pink ... Company,s breast endoscopy product line, the MammoView(TM), ... Surgical Products Magazine in the December 2008 issue. ... allow Physicians direct visualization, while examining lesions in ...
Cached Medicine News:Health News:Siemens Survey Reveals Low Awareness of Escalating Need for Superior Data Center Efficiency 2Health News:Siemens Survey Reveals Low Awareness of Escalating Need for Superior Data Center Efficiency 3Health News:Shared Health(R) Proves Health Information Exchange (HIE)Success in Tennessee 2Health News:Shared Health(R) Proves Health Information Exchange (HIE)Success in Tennessee 3Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 2Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 3Health News:Two-Drug Combo May Lower Diabetics' Kidney Risk 2Health News:Recession Spawns Vital New Industry - Financial Wellness 2Health News:Recession Spawns Vital New Industry - Financial Wellness 3Health News:Solos Endoscopy, Inc.'s MammoView(TM) Featured in December Issue of Surgical Products Magazine 2
... the needs of the higher risk ... features the PneumaticWalker for Diabetics. Similar ... Diabetics incorporates an innovative dual density ... insole, when combined with the semi-rigid ...
... Sarmiento style Patella-Tendon-Bearing brace is designed for ... tibia and fibula. The tibial crest provides ... medullary nailing and removal of internal or ... of joints above and below the fracture ...
... VACOPED is a revolutionary cast replacement ... the lower leg and foot. , ... patient's anatomy and in conjunction with a ... the general time of fracture or rupture ...
... combines the therapeutic benefits of controlled compression ... to minimize pain. The cuff is anatomically ... maximum cryotherapy.,All Cryo/Cuffs can be ordered as ... (including a tube assembly and insulation disk). ...
Medicine Products: